Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

BI-1206

😃Good
Catalog No. T9901A-951

BI-1206 is a recombinant antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). It inhibits CD20 internalization induced by Rituximab, whether used alone or in combination with drugs such as Ibrutinib, Venetoclax, and CHOP. BI-1206 can enhance or restore the activity of Rituximab or other anti-CD20 monoclonal antibodies and demonstrates cytolytic activity against malignant B cells. BI-1206 is applicable in research on cancers such as mantle cell lymphoma (MCL).

BI-1206

BI-1206

😃Good
Catalog No. T9901A-951
BI-1206 is a recombinant antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). It inhibits CD20 internalization induced by Rituximab, whether used alone or in combination with drugs such as Ibrutinib, Venetoclax, and CHOP. BI-1206 can enhance or restore the activity of Rituximab or other anti-CD20 monoclonal antibodies and demonstrates cytolytic activity against malignant B cells. BI-1206 is applicable in research on cancers such as mantle cell lymphoma (MCL).
Pack SizePriceAvailabilityQuantity
1 mgInquiryBackorder
5 mgInquiryBackorder
Bulk & Custom
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
View More

Product Introduction

Bioactivity
Description
BI-1206 is a recombinant antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). It inhibits CD20 internalization induced by Rituximab, whether used alone or in combination with drugs such as Ibrutinib, Venetoclax, and CHOP. BI-1206 can enhance or restore the activity of Rituximab or other anti-CD20 monoclonal antibodies and demonstrates cytolytic activity against malignant B cells. BI-1206 is applicable in research on cancers such as mantle cell lymphoma (MCL).
In vitro
BI-1206 (5 μg/mL, 0-5 hours) effectively blocks Rituximab (5 μg/mL)-induced CD20 internalization in JeKo-1 cells, as well as Rituximab-based induction when combined with Ibrutinib, Venetoclax, or CHOP.
In vivo
BI-1206, administered at 10 mg/kg via intravenous injection twice weekly, effectively inhibits tumor growth in ibrutinib-venetoclax dual-resistant MCL PDX (PDX-A) NSG mouse models. When combined with rituximab, it suppresses tumor progression in rituximab-ibrutinib-CAR T triple-resistant MCL PDX (PDX-B) NSG mouse models. The combination of BI-1206 with ibrutinib or venetoclax in NSG mouse models results in enhanced efficacy and prolonged survival over 14 days. Additionally, BI-1206, in combination with venetoclax, exhibits superior antitumor activity and extends survival compared to any single or dual regimen in ibrutinib-rituximab-venetoclax triple-resistant MCL PDX (PDX-C) mouse models.
Chemical Properties
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% Saline/PBS/ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLSaline/PBS/ddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Sci Citations

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy BI-1206 | purchase BI-1206 | BI-1206 cost | order BI-1206 | BI-1206 in vivo | BI-1206 in vitro